Tag:

#Womens Health

Health

Doctors Dismissed My Symptoms for Years—Now I Help Other Women Get Answers 

by Chief Editor
written by Chief Editor

The Long Road to Diagnosis: Why Women’s Pain is Still Dismissed

For years, Sophie Richards’s debilitating pain was dismissed as “dramatic” or simply “bad periods.” Her story, recently highlighted in Newsweek, is tragically common. It underscores a critical issue in healthcare: the systemic dismissal of women’s pain and the lengthy, often frustrating, journey to a proper diagnosis. Richards’s experience, ultimately revealed as endometriosis, is a stark reminder of the require for greater awareness, improved medical education, and a shift in how women’s health concerns are addressed.

The Endometriosis Delay: A Decade of Suffering

Endometriosis affects roughly 1.5 million people in the U.K. And 10-15% of women of reproductive age in the U.S. Despite these numbers, diagnosis often takes seven to ten years. This delay isn’t simply inconvenient; it can have devastating consequences for women’s physical and mental health, impacting their education, careers, and overall quality of life. Richards’s story exemplifies this, as her symptoms interfered with her studies and led to years of feeling unheard and ashamed.

Misdiagnosis and the Cycle of Doubt

The path to diagnosis is often riddled with missteps. Richards faced suggestions that her symptoms were due to a sexually transmitted disease, leading to feelings of humiliation and further distrust in the medical system. This highlights a dangerous pattern: when women’s pain isn’t readily explained, it’s often attributed to psychological factors or lifestyle choices, rather than being taken seriously as a potential physical ailment. The normalization of “bad periods” also contributes to the problem, leading many women to believe their pain is simply something they must endure.

The Power of Self-Advocacy and Research

Frustrated with the lack of answers, Richards took matters into her own hands, embarking on extensive self-research. She discovered the connection between her symptoms and inflammation, leading her to explore various dietary and lifestyle changes. This proactive approach, while empowering, shouldn’t be necessary. It underscores the need for doctors to be better equipped to recognize and diagnose conditions like endometriosis promptly.

The Role of Inflammation in Chronic Conditions

Richards’s journey revealed that addressing the underlying inflammation was key to managing her symptoms. This aligns with growing research highlighting the role of inflammation in a wide range of chronic conditions, not just endometriosis. An anti-inflammatory lifestyle, focusing on diet, gut health, exercise, sleep, stress management, and detoxification, can be a powerful tool for improving overall health and well-being.

A Call for Education and Early Intervention

Richards advocates for comprehensive menstrual health education, starting at a young age for both boys and girls. She believes that destigmatizing conversations about periods and teaching individuals to recognize the difference between normal discomfort and potentially serious symptoms is crucial. Early education could empower individuals to advocate for themselves and encourage healthcare professionals to take women’s pain seriously.

Future Trends in Women’s Health

Several trends suggest a potential shift in women’s healthcare:

  • Increased Awareness: Advocates like Sophie Richards are raising awareness through social media and personal storytelling, challenging the status quo and demanding better care.
  • Focus on Holistic Approaches: There’s a growing interest in holistic approaches to women’s health, recognizing the interconnectedness of physical, mental, and emotional well-being.
  • Technological Advancements: New technologies, such as at-home hormone testing and symptom tracking apps, are empowering women to monitor their health and gather data to share with their doctors.
  • Specialized Training: Increased demand for specialized training in women’s health for medical professionals.

FAQ

Q: What is endometriosis?
A: Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside the womb, causing inflammation and pain.

Q: Why does it take so long to diagnose endometriosis?
A: Symptoms are often dismissed or misdiagnosed, and awareness among healthcare professionals can be limited.

Q: Can diet and lifestyle changes help with endometriosis?
A: An anti-inflammatory lifestyle, focusing on diet, gut health, and stress management, can help manage symptoms.

Q: Where can I locate more information about endometriosis?
A: Resources like Endometriosis UK and the American Endometriosis Association offer valuable information and support.

Did you know? One in ten women in Wales suffer from endometriosis.

Pro Tip: Keep a detailed symptom diary to share with your doctor. This can help them identify patterns and build a more accurate diagnosis.

Share your story! Have you experienced delays in diagnosis or dismissal of your pain? Leave a comment below and let’s continue the conversation.

0 comments
0 FacebookTwitterPinterestEmail
Health

‘I had no idea’: The hidden mental health struggles many women face during menopause

by Chief Editor
written by Chief Editor

The Silent Crisis: Why Women’s Mental Health is Finally Taking Center Stage During Menopause

For decades, menopause has been largely dismissed as a natural part of aging, with symptoms often brushed aside or misdiagnosed. However, a growing body of evidence reveals a far more complex picture – one where the hormonal shifts of perimenopause and menopause significantly impact women’s mental health, often with devastating consequences. Across Europe, and particularly in the United Kingdom, awareness is finally rising, but significant gaps in understanding and care remain.

The Shocking Statistics: A Gap in Knowledge

Recent data paints a concerning picture. A YouGov survey commissioned by the Royal College of Psychiatrists in the UK found that only 28 percent of women understood that menopause could trigger a modern mental illness. This lack of awareness is directly linked to delayed diagnosis and treatment, leaving countless women to suffer in silence. The scale of the issue is substantial; a large European study revealed that 55 percent of women experience psychological symptoms like mood swings, anxiety, or depression during menopause.

Beyond Hot Flashes: The Mental Health Spectrum

The impact extends beyond simply feeling “down.” Fluctuations in estrogen and progesterone can trigger a range of mental health challenges. These include increased anxiety, panic attacks, difficulty concentrating, and even a heightened risk of depression. Research indicates perimenopause can raise the risk of first-time major depression by around 30 percent and increase the likelihood of manic episodes in women predisposed to bipolar disorder. Perhaps most alarmingly, a 2026 study highlighted that approximately 1 in 6 women experience suicidal thoughts during perimenopause and menopause, often going unidentified and untreated.

The Black Women’s Health Disparity

The challenges are not evenly distributed. A University College London study revealed a stark disparity: 88 percent of Black women received no menopause education at school, and over half felt completely uninformed before the age of 40. This lack of education contributes to delayed diagnosis and appropriate care within this community.

Misdiagnosis and the Long Road to Relief

Sonja Rincón, founder of the AI-powered menopause tracking app Menotracker, shared a personal story that resonates with many. Her own symptoms, beginning in her mid-thirties, were initially misdiagnosed as depression. Years were spent cycling through antidepressants that failed to address the root cause – hormonal changes. This experience underscores a critical issue: the need for healthcare professionals to recognize and understand the link between menopause and mental health.

Workplace Impacts and the Call for Change

The impact of menopause extends beyond individual well-being, affecting women’s professional lives. A 2025 international study by Astellas Pharma found that nearly one in 12 women felt discriminated against at work due to menopause, with many experiencing reduced productivity or fearing disclosure of their symptoms. This highlights the urgent need for workplace policies that support women experiencing menopause.

The Rise of Menopause Awareness and MHT

Fortunately, the tide is turning. Increased awareness, fueled by social media and the publication of new scientific data demonstrating a more favorable benefit/risk ratio with menopausal hormone therapy (MHT), is driving a significant rise in MHT prescriptions in the United Kingdom. Accessibility to accurate information and guidance from respected institutions is a key driver of this change. Standardized education for healthcare professionals is also crucial to ensure equitable and safe care.

The Power of Tracking and Personalized Care

Innovative tools like Menotracker are empowering women to take control of their health. By tracking symptoms, cycles, and treatment responses, women can generate detailed reports to share with their doctors, leading to more accurate diagnoses and personalized treatment plans.

Looking Ahead: Future Trends in Menopause Care

The future of menopause care will likely focus on several key areas:

Personalized Hormone Therapy

Moving beyond a one-size-fits-all approach to hormone therapy, future treatments will likely be tailored to individual needs based on genetic factors, symptom profiles, and overall health status.

AI-Powered Diagnostics

Artificial intelligence will play an increasingly important role in diagnosing and managing menopause, with tools like Menotracker providing valuable data insights for healthcare professionals.

Integrated Mental Health Support

Recognizing the strong link between menopause and mental health, integrated care models will become more common, offering women access to both hormonal and psychological support.

Workplace Menopause Policies

More companies will implement menopause-friendly workplace policies, including flexible working arrangements, access to support groups, and training for managers.

FAQ

Q: What are the early signs of perimenopause?
A: Common early signs include changes in menstrual cycle length, hot flashes, sleep disturbances, mood swings, and difficulty concentrating.

Q: Is hormone therapy safe?
A: Recent research suggests MHT is generally safe for most women when prescribed appropriately. The benefits and risks should be discussed with a healthcare professional.

Q: How can I find support for menopause?
A: Resources include your doctor, menopause support groups, online communities, and apps like Menotracker.

Q: What role does education play in menopause care?
A: Increased education for both women and healthcare professionals is crucial for improving awareness, diagnosis, and treatment.

Did you know? The average length of menopause symptoms varies by country, with women in Sweden reporting moderate or severe symptoms in 60% of cases in 2021.

Pro Tip: Keep a detailed symptom diary to share with your doctor. This can help them understand your individual experience and develop a personalized treatment plan.

Have you experienced challenges navigating menopause? Share your story in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Mom’s late-stage cancer symptoms dismissed by multiple doctors for years

by Chief Editor
written by Chief Editor

The Rising Tide of Colorectal Cancer in Younger Adults: A Wake-Up Call

A growing number of individuals in their 30s and 40s are receiving a colorectal cancer diagnosis, challenging conventional understanding of the disease. Marisa Peters, a 44-year-old Los Angeles mother of three, embodies this shift. For years, her symptoms – rectal bleeding, changes in bowel movements, and urgent needs to proceed – were dismissed as lingering effects of childbirth. It wasn’t until she was diagnosed with stage 3 colorectal cancer that the true cause was revealed.

Dismissed Symptoms and Delayed Diagnoses

Peters’ story isn’t unique. Doctors often attribute early symptoms to common postpartum issues, leading to delayed investigations. This is particularly concerning given that colorectal cancer is now the leading cause of cancer death in adults under 50, and the second leading cause overall in the United States. In 1995, adults 65 and younger comprised 27% of all new cases; today, that number has risen to nearly 45%.

“They didn’t realize the face of colorectal cancer had changed,” Peters explained to Fox News Digital. “It now looked like someone much younger.” The increasing incidence in younger populations highlights the need for greater awareness among both patients and healthcare providers.

The Importance of Early Screening

While Peters’ cancer was already advanced by the time of diagnosis, she emphasizes the importance of colonoscopies for those with concerns or risk factors. A colonoscopy is considered the “gold standard” for screening. Her sister, after learning of Peters’ diagnosis, underwent a colonoscopy and had pre-cancerous polyps removed, despite experiencing no symptoms. Peters also discovered her parents had previously removed pre-cancerous polyps.

“Knowing your family’s health history is tremendously essential,” Peters stated.

Beyond Genetics: Understanding the Shift

The reasons behind this surge in young-onset colorectal cancer remain unclear, but researchers are investigating potential contributing factors. While genetics play a role, the increase suggests environmental and lifestyle influences are also at play.

Taking Action: BE SEEN and Community Support

Driven by her experience, Peters co-founded BE SEEN, a nonprofit dedicated to advocating for earlier intervention and screening. The organization promotes resources and community programs, including “poop parties” designed to reduce anxiety and stigma surrounding colonoscopies.

BE SEEN aims to empower individuals to advocate for their health and seek timely medical attention when experiencing concerning symptoms. The organization also works to raise awareness about the changing face of colorectal cancer and the need for proactive screening.

What Symptoms Should You Watch For?

Recognizing the early warning signs is crucial. Key symptoms to be aware of include:

  • Rectal bleeding
  • Changes in bowel habits (diarrhea, constipation, or a change in the consistency of stool)
  • Persistent abdominal discomfort or cramping
  • A feeling of incomplete evacuation
  • Unexplained anemia

It’s important to remember that these symptoms can be caused by other conditions, but any persistent changes should be evaluated by a medical professional.

FAQ: Colorectal Cancer and Young Adults

Q: At what age should I start getting screened for colorectal cancer?
A: Official health agencies recommend starting screenings at age 45 for adults at average risk.

Q: I’m experiencing some of these symptoms. Should I be worried?
A: It’s always best to consult with a doctor to discuss your symptoms and determine the appropriate course of action.

Q: Is colorectal cancer preventable?
A: Colorectal cancer is often preventable through regular screening and the removal of pre-cancerous polyps.

Q: What is a colonoscopy?
A: A colonoscopy is a procedure where a doctor uses a long, flexible tube with a camera to examine the entire colon for polyps or other abnormalities.

Did you know? Colorectal cancer is highly treatable when detected early. Early detection significantly improves survival rates.

Pro Tip: Don’t hesitate to advocate for yourself. If you feel your concerns are being dismissed, seek a second opinion.

If you are experiencing any concerning symptoms, please consult with your healthcare provider. Early detection is key to improving outcomes. Learn more about colorectal cancer and screening options from reputable sources like the American Cancer Society.

Share this article with your friends and family to help raise awareness about this important health issue.

0 comments
0 FacebookTwitterPinterestEmail
Health

Women bleed too: HFA – Medical Republic

by Chief Editor
written by Chief Editor

Haemophilia Research Shifts Focus to Female Experiences: A New Era of Diagnosis and Care

Haemophilia Foundation Australia (HFA) is spearheading a crucial initiative to better understand the healthcare experiences of women and girls living with bleeding disorders. A new survey, launched by the HFA, aims to address a historical gap in research and improve diagnosis, treatment, and overall care for this often-overlooked population.

The Underdiagnosis Challenge in Female Bleeding Disorders

For years, bleeding disorders like haemophilia and von Willebrand disease have been predominantly studied in males. What we have is largely due to the fact that these conditions are X-linked recessive, meaning they primarily manifest in males who have only one X chromosome. Still, females, with two X chromosomes, can also be affected, either as carriers or by experiencing symptoms themselves.

The HFA highlights that approximately 20-30% of females who carry a haemophilia-causing gene mutation experience reduced clotting factor levels, leading to bleeding symptoms and, in some cases, haemophilia. These symptoms can include easy bruising, heavy or prolonged menstrual periods, and prolonged bleeding after medical procedures or injuries.

What the New Survey Aims to Uncover

The HFA survey delves into the challenges women and girls face when advocating for their health in various healthcare settings – from general practitioner visits to emergency department encounters and specialist appointments. It seeks to identify useful tools and resources, such as patient information cards, period diaries, and fact sheets, that can empower patients and their families to navigate the healthcare system more effectively.

Responses will be deidentified and shared with the HFA’s Women and Girls Advisory Group, ensuring the findings directly inform the Foundation’s efforts in representation, education, and research.

Beyond Haemophilia: Expanding the Understanding of Bleeding Disorders

Whereas the survey specifically mentions haemophilia, it’s open to all women and girls with any bleeding disorder, as well as those who are carriers of the gene. This inclusive approach reflects a growing understanding of the diverse range of bleeding disorders and the need for comprehensive research.

The Australian Haemophilia Centre Directors’ Organisation (AHCDO) emphasizes the importance of connecting individuals with bleeding disorders to the HFA, the national peak body representing those affected and their families.

Future Trends: Personalized Medicine and Enhanced Support

This survey represents a shift towards more personalized medicine in the treatment of bleeding disorders. By understanding the specific challenges faced by women and girls, healthcare providers can tailor treatment plans and support services to meet their individual needs.

Expect to see increased development of resources specifically designed for female patients, including improved diagnostic tools for identifying bleeding disorders in women and more effective management strategies for heavy menstrual bleeding and other gender-specific symptoms.

the focus on patient empowerment – through tools like patient cards and period diaries – aligns with a broader trend in healthcare towards shared decision-making and patient-centered care.

FAQ

Q: Who can participate in the survey?
A: Women and girls with bleeding disorders (or who are carriers of the gene), along with their partners or family members who have accompanied them to medical appointments.

Q: What is the deadline for completing the survey?
A: The survey closes at midnight (AEST) on Wednesday, April 8, 2026.

Q: Where can I find more information about the survey?
A: You can contact HFA on 03 9885 7800 or at [email protected].

Q: What is the role of the Women and Girls Advisory Group?
A: The group will analyze the survey results and use them to guide the HFA’s efforts in representation, education, and research.

Q: Where can I learn more about bleeding disorders?
A: Visit the Haemophilia Foundation Australia website at https://www.haemophilia.org.au/ or the National Blood Authority website at https://www.blood.gov.au/clinical-guidance/bleeding-disorders-clinical.

Pro Tip: Preserve a detailed record of your bleeding episodes, including the date, severity, and any associated symptoms. This information can be invaluable when discussing your condition with your healthcare provider.

Have you or a loved one been affected by a bleeding disorder? Share your experiences in the comments below. To stay informed about the latest developments in bleeding disorder research and care, visit the Haemophilia Foundation Australia website.

0 comments
0 FacebookTwitterPinterestEmail
Business

Women with Asherman’s syndrome call for tighter control of outdated practices

by Chief Editor
written by Chief Editor

The Silent Scar: Why Women Are Demanding Change to D&C Procedures

A common procedure following miscarriage, abortion, or childbirth – the dilation and curettage (D&C) – is facing increased scrutiny as women share harrowing stories of uterine scarring and infertility. Advocates and medical professionals are calling for tighter regulations and a shift towards safer practices, highlighting a potential turning point in women’s healthcare.

Asherman’s Syndrome: A Hidden Risk

Lily Johnstone, a Melbourne resident, dreamed of expanding her family. That dream is now uncertain after a D&C left her with Asherman’s syndrome, a condition characterized by scarring inside the uterus. “At the moment it kind of feels like that’s been taken away from me, so it’s very sad,” she shared. Ms. Johnstone’s experience isn’t isolated. Between 1 to 2 percent of women develop Asherman’s syndrome after undergoing a D&C.

The condition can lead to changes in menstruation, painful periods, and difficulty conceiving. It likewise carries risks of infection, complications during pregnancy, and even catastrophic bleeding after delivery.

Outdated Tools and a Lack of Accountability

At the heart of the concern is the continued leverage of sharp curettes – a looped metal tool with a cutting edge – despite recommendations from the World Health Organization (WHO) to utilize suction curettes, a blunt plastic tool, instead. The sharp curette, dating back to the 1840s, is considered by some, like obstetrician Thierry Vancaillie, a “museum piece” intended for diagnostic sampling, not treatment of miscarriage.

Advocates like Naomi Cate, co-founder of Asherman’s Australia, express frustration with the lack of regulatory change. “That reflects very low respect for women,” she stated. Ms. Cate herself was diagnosed with the condition after a postpartum D&C she was later told was unnecessary, and now advocates for safer treatment options.

A key issue is the absence of mandatory reporting of Asherman’s syndrome cases. Currently, the Therapeutic Goods Administration (TGA) classifies sharp curettes as a low-risk device, meaning adverse events don’t need to be reported, creating a data gap that hinders understanding the true scope of the problem.

The Push for Clinical Standards and Data Collection

The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) issued guidelines last year recommending against the use of sharp curettes in D&Cs following miscarriage, but no such guidelines exist for postpartum procedures. RANZCOG president Dr. Nisha Khot expressed a desire to spot suction curettes used whenever possible.

Professor Vancaillie advocates for the routine use of ultrasound imaging during D&Cs to ensure complete tissue removal and minimize the risk of scarring. While beneficial, ultrasound isn’t universally available in surgical theaters, and not all clinicians are trained in its use.

The lack of comprehensive data is a significant obstacle. Dr. Khot emphasizes the need for an Asherman’s syndrome registry and increased research funding to better understand the condition and improve treatment outcomes.

What Does the Future Hold?

The growing awareness of Asherman’s syndrome and the potential risks associated with D&C procedures are likely to drive several key changes in women’s healthcare:

  • Increased Regulation: Pressure will likely mount on regulatory bodies like the TGA to reclassify sharp curettes and mandate adverse event reporting.
  • Wider Adoption of Suction Curettage: Hospitals and clinics will likely transition towards using suction curettage as the standard method for D&C procedures.
  • Enhanced Ultrasound Utilization: Investment in ultrasound technology and training for clinicians will develop into more common to improve procedural accuracy and minimize complications.
  • Improved Informed Consent: Clinicians will be expected to provide more detailed information to patients about the risks and benefits of D&C procedures, including the potential for Asherman’s syndrome.
  • National Registries and Research: The establishment of national registries to track Asherman’s syndrome cases will be crucial for gathering data and informing future research efforts.

Frequently Asked Questions

What is Asherman’s syndrome? Asherman’s syndrome is a condition where scar tissue forms inside the uterus, often after a D&C procedure.

What are the symptoms of Asherman’s syndrome? Symptoms can include changes in menstrual cycles, painful periods, and difficulty getting pregnant.

Is a D&C always necessary? A D&C is often necessary to remove pregnancy tissue, but alternative methods should be considered when appropriate.

What can I do if I suspect I have Asherman’s syndrome? Consult with a gynecologist specializing in reproductive health for diagnosis and treatment options.

What is the difference between a sharp curette and a suction curette? A sharp curette has a cutting edge and can cause more scarring, while a suction curette uses gentle suction to remove tissue.

Did you know? The risk of developing Asherman’s syndrome after a D&C is relatively low (1-2%), but the consequences can be life-altering.

Pro Tip: Don’t hesitate to ask your doctor about all available options and potential risks before undergoing a D&C procedure.

Have you had a D&C and experienced complications? Share your story in the comments below to help raise awareness and support other women.

0 comments
0 FacebookTwitterPinterestEmail
Health

This Women’s Health Research Month, let’s talk about menopause

by Chief Editor
written by Chief Editor

The Silent Struggle: Why Menopause is Finally Getting the Attention It Deserves

For generations, menopause has been framed as an inevitable decline, something women were simply expected to “get through.” But a growing movement, spearheaded by researchers and clinicians like Dr. Lina Huang at the McGill University Health Centre (MUHC), is challenging that narrative. It’s a shift fueled by a recognition that menopause isn’t just a biological process, but a significant health transition impacting half the population – and one that has been historically understudied, and underfunded.

The Research Gap: A $1 Trillion Opportunity

Dr. Huang highlights a stark reality: “Menopause is something half the population will experience, yet it remains one of the least studied areas of medicine.” This lack of research translates to a significant gap in understanding hormone therapy, cardiovascular risks, and cancer implications. The consequences extend beyond individual well-being. A 2024 McKinsey Health Institute report, Closing the Women’s Health Gap, estimates that improving women’s health research and care could have a $1 trillion global impact, boosting economies and improving quality of life.

In Canada alone, the report suggests a $37 billion economic opportunity exists by addressing the unmet needs of women experiencing menopausal symptoms. Unmanaged symptoms can lead to decreased perform productivity, lost earning potential, and reduced community engagement.

The MUHC’s Complex Menopause Clinic: A Specialized Approach

Recognizing this critical need, the MUHC established a Complex Menopause Clinic, led by Dr. Huang. This clinic addresses a crucial gap in care for women whose menopausal treatment isn’t straightforward – those with a history of cancer, stroke, or cardiovascular risk factors. “While most gynecologists are well versed in managing menopause, access to specialized care becomes significantly more challenging for patients with higher-risk profiles,” explains Dr. Huang.

The clinic’s collaborative model, involving oncologists, cardiologists, and other specialists, reflects the multifaceted nature of hormonal health. It emphasizes that hormone therapy isn’t the only solution, offering non-hormonal alternatives to alleviate debilitating symptoms like hot flashes and insomnia.

Beyond Hormone Therapy: A Holistic View of Menopause

Menopause’s impact extends far beyond hot flashes. It can disrupt sleep, affect mental clarity and mood, influence sexual health, impact bone density, and even affect cognitive function. The experience can experience like a process of relearning one’s body, often without adequate guidance.

Dr. Huang emphasizes the importance of listening to patients and treating their individual symptoms. “When patients come to the clinic and ask for facilitate, it’s really as simple as listening to them and treating their symptoms,” she explains.

The Forward Fund: Investing in Women’s Health Futures

The MUHC Foundation’s $5 million Forward Fund for Women’s Health is a direct response to the historical underrepresentation of women in medical research. Marie-Hélène Laramée, President and CEO of the MUHC Foundation, states, “The Forward Fund was born from our collective commitment to change that.” The fund aims to accelerate discovery, advance women’s healthcare, and prioritize innovation and compassion.

Normalizing the Conversation: Perimenopause and Beyond

Increased public awareness surrounding perimenopause – the transitional phase leading up to menopause – is a positive step. Normalizing conversations about these experiences empowers women to recognize symptoms, seek care, and make informed decisions. Dr. Huang notes that many issues evolve over years, not appearing suddenly at menopause.

Did you know? Women spend an average of nine more years than men in poor health or with some degree of disability, according to the McKinsey Health Institute.

Future Trends in Women’s Health

Several trends are poised to shape the future of women’s health, particularly in the context of menopause:

  • Personalized Medicine: Tailoring treatments based on individual genetic profiles and hormonal levels will become increasingly common.
  • Digital Health Tools: Apps and wearable devices will play a larger role in tracking symptoms, providing support, and connecting women with healthcare providers.
  • AI-Powered Diagnostics: Artificial intelligence can help assess cardiovascular risk in menopausal patients and personalize treatment plans.
  • Increased Funding for Research: Growing awareness and advocacy efforts are expected to drive increased investment in women’s health research.
  • Focus on Preventative Care: Emphasis will shift towards proactive strategies to manage menopausal symptoms and prevent long-term health complications.

FAQ: Menopause and Women’s Health

  • What is perimenopause? It’s the transitional phase leading up to menopause, often beginning up to a decade before a woman’s final menstrual period.
  • Is hormone therapy safe? The safety of hormone therapy depends on individual risk factors and should be discussed with a healthcare provider.
  • What are some non-hormonal treatments for menopause? Lifestyle changes, cognitive behavioral therapy, and certain medications can help manage symptoms.
  • Where can I learn more about the MUHC’s Complex Menopause Clinic? Information can be found on the MUHC website.

Pro Tip: Don’t hesitate to advocate for your health. Ask questions, seek second opinions, and find a healthcare provider who understands your needs.

To learn more about supporting the MUHC Foundation’s Forward Fund for Women’s Health, visit https://muhcfoundation.com/works/womens-health-reimagined.

What questions do you have about menopause and women’s health? Share your thoughts in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Long-term aspirin use is associated with lower ovarian cancer risk

by Chief Editor
written by Chief Editor

Aspirin’s Potential Role in Reducing Ovarian Cancer Risk: A New Look at Prevention

Ovarian cancer remains a significant health challenge, ranking as a leading cause of gynecological cancer mortality globally. The difficulty in early detection, due to vague and often overlooked symptoms like bloating, decreased appetite, and abdominal pain, contributes to the majority of cases being diagnosed at advanced stages. This late-stage diagnosis often translates to poorer prognoses and higher treatment costs. However, emerging research suggests a potential preventative measure: frequent aspirin use.

The Hurwitz Study: Long-Term Aspirin Use and Ovarian Cancer

A study published in The International Journal of Epidemiology in February 2026, led by Lauren Hurwitz and colleagues, investigated the association between aspirin use and ovarian cancer risk. Researchers pooled data from nine US-based and one Swedish prospective cohort studies, encompassing a substantial 675,901 participants. The study focused on individuals with at least one intact ovary and no prior history of ovarian cancer.

The research defined “frequent aspirin use” as consuming the medication at least five days per week for a minimum of six months, regardless of dosage. Ovarian cancer incidence was tracked through questionnaires, medical records, and cancer registry data. The findings revealed a compelling correlation: frequent, long-term aspirin use (over six years) was associated with a 14% reduction in ovarian cancer risk.

How Might Aspirin Offer Protection?

Even as the study establishes an association, the underlying mechanisms are still being explored. Researchers hypothesize that aspirin’s protective effect may stem from its ability to inhibit pro-inflammatory mediators. These mediators play a role in inflammatory signaling, cellular proliferation, angiogenesis (the formation of new blood vessels), invasion, and metastasis – all processes involved in cancer development. Aspirin may also influence pathways directly relevant to ovarian carcinogenesis.

Pro Tip: Don’t start taking aspirin regularly without consulting your doctor. Long-term medication use carries potential risks and side effects that demand to be carefully considered.

Future Trends: The Growing Incidence of Ovarian Cancer and the Need for Prevention

Despite advancements in treatment, the incidence of ovarian cancer is projected to rise. GlobalData epidemiologists forecast an increase from 68,000 diagnosed cases per year in 2026 to 71,000 cases per year in 2032 across the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan). This underscores the critical importance of preventative strategies.

Tailored prevention plans, incorporating factors like aspirin use – when deemed appropriate by a healthcare professional – could play a significant role in mitigating the growing disease burden. Further research is needed to identify individuals who would benefit most from aspirin prophylaxis and to determine the optimal dosage and duration of treatment.

Understanding the Challenges of Ovarian Cancer Diagnosis

One of the biggest hurdles in combating ovarian cancer is its often-vague symptom presentation. Symptoms like abdominal pain, bloating, and feeling full quickly are common to many less serious conditions, leading to delayed diagnosis. This highlights the need for increased awareness among both patients and healthcare providers.

Did you understand? Roughly 80% of ovarian cancer cases are diagnosed at stage III or IV, significantly impacting treatment options and outcomes.

Frequently Asked Questions (FAQ)

Q: Is aspirin a cure for ovarian cancer?
A: No, aspirin is not a cure. The study suggests it may reduce the risk of developing ovarian cancer, but it does not treat existing cancer.

Q: Should I start taking aspirin daily to prevent ovarian cancer?
A: No. You should always consult with your doctor before starting any new medication regimen, including aspirin. Aspirin has potential side effects and may not be suitable for everyone.

Q: What are the other risk factors for ovarian cancer?
A: Factors such as age, family history of ovarian or breast cancer, and genetic mutations can increase your risk. Discuss your individual risk factors with your doctor.

Q: What symptoms should I be aware of?
A: Pay attention to persistent bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and changes in bowel or bladder habits. If these symptoms persist for more than two weeks, consult your doctor.

Wish to learn more about women’s health and cancer prevention? Explore resources from the CDC.

What are your thoughts on preventative measures for ovarian cancer? Share your comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Another women’s health service in Maine is closing

by Chief Editor
written by Chief Editor

Maine’s Maternal Care Crisis: A Bangor Practice Closure Signals Wider Trends

The closure of Downeast OB/GYN in Bangor, Maine, on July 2, 2026, is the latest sign of a growing challenge in maternal healthcare access across the state. This follows the closure of at least ten hospital birthing centers in Maine over the past decade, raising significant concerns for expectant mothers and healthcare providers alike.

The Ripple Effect of Physician Shortages

Dr. Christopher Rumsey, who took ownership of Downeast OB/GYN in 2019, cited the inability to recruit new physicians as the primary driver behind the difficult decision to close the practice. The recent departure of two physician partners and a midwife left Dr. Rumsey facing unsustainable on-call demands – 24 hours a day, seven days a week. This situation highlights a critical issue: the strain on existing providers and the difficulty of maintaining comprehensive care in a private practice setting.

The problem isn’t isolated to Bangor. Maine, like many states, is grappling with a shortage of healthcare professionals, particularly in specialized fields like obstetrics and gynecology. This shortage is exacerbated by factors such as an aging physician population, burnout, and the challenges of practicing in rural areas.

From Private Practice to Hospital Systems: A Shift in Care Delivery

Dr. Rumsey’s decision to join Women’s Healthcare of Maine at Northern Light Eastern Maine Medical Center reflects a broader trend: a move from independent private practices towards larger hospital systems. Even as this transition can offer benefits like shared resources and reduced on-call burdens, it too raises questions about the future of personalized care and patient choice.

The remaining members of the Downeast OB/GYN team – two certified family nurse practitioners – are currently evaluating their options, with a hope to remain in the area and continue serving their patients. Their future plans underscore the uncertainty facing healthcare professionals as practices consolidate and the landscape of maternal care evolves.

What Does This Mean for Maine Families?

The closure of Downeast OB/GYN will undoubtedly impact access to OB/GYN services for women in the Bangor area. Patients will need to seek care from alternative providers, potentially traveling longer distances or facing longer wait times for appointments. This is particularly concerning for women with high-risk pregnancies or those requiring specialized care.

The situation also highlights the vital role of nurse practitioners and midwives in providing maternal healthcare. As physician shortages persist, these professionals will likely play an increasingly essential role in ensuring access to care, particularly in underserved areas.

Looking Ahead: Potential Solutions and Future Trends

Addressing the maternal care crisis in Maine will require a multi-faceted approach. Potential solutions include:

  • Incentivizing medical professionals to practice in rural areas: Loan repayment programs, tax breaks, and other incentives can attract and retain healthcare providers in underserved communities.
  • Expanding the role of telehealth: Telehealth can improve access to care for patients in remote areas and reduce the burden on in-person providers.
  • Investing in training programs: Increasing the number of residency slots and training opportunities for OB/GYNs and other maternal healthcare professionals is crucial.
  • Supporting collaborative care models: Encouraging collaboration between hospitals, private practices, and community health centers can improve care coordination and access.

The trend towards consolidation within healthcare systems is likely to continue, as practices seek to leverage economies of scale and address staffing challenges. However, it’s essential to ensure that this consolidation doesn’t approach at the expense of patient-centered care and access to services.

FAQ

Q: When is Downeast OB/GYN closing?
A: July 2, 2026.

Q: Why is Downeast OB/GYN closing?
A: The primary reason is the inability to recruit new physicians to the private practice setting, leading to unsustainable on-call demands for the remaining physician.

Q: Where is Dr. Rumsey going after the practice closes?
A: He will be joining Women’s Healthcare of Maine at Northern Light Eastern Maine Medical Center.

Q: What does this mean for patients of Downeast OB/GYN?
A: Patients will receive written notification of the closure and will need to find alternative care providers.

Pro Tip: If you are seeking OB/GYN care in Maine, it’s important to research your options and schedule appointments well in advance, given the current challenges in access to care.

Have questions about the changing landscape of maternal healthcare in Maine? Share your thoughts in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Battle to get ‘female Viagra’ to market — and how ‘Grey’s Anatomy’ played a role

by Chief Editor
written by Chief Editor

The Ongoing Quest for Female Sexual Wellness: Beyond the “Pink Pill”

For decades, pharmaceutical solutions for male sexual dysfunction, like Viagra and Cialis, have been readily available. Yet, a comparable option for women has been a more elusive goal. Now, a new documentary, “The Pink Pill: Sex, Drugs & Who Has Control,” premiering on Paramount+, shines a spotlight on Addyi, the first FDA-approved pill aimed at treating hypoactive sexual desire disorder (HSDD) in women, and the challenging path it took to market.

Addyi has undergone a few makeovers before hitting pharmacy shelves. It was once an antidepressant before evolving into medicine to address low sex drive. Courtesy of Paramount

From Antidepressant to Addressing HSDD

Initially developed by Boehringer Ingelheim as an antidepressant, the pill, clinically known as flibanserin, didn’t prove effective for depression. Researchers then explored its potential to address HSDD, a condition characterized by low or no sex drive for at least six months. Addyi works differently than medications like Viagra, which increase blood flow. Instead, it focuses on balancing neurotransmitters – dopamine, serotonin, and norepinephrine – in the brain to potentially boost sexual desire.

A Rocky Road to FDA Approval

The journey to FDA approval was far from smooth. The drug faced two rejections in 2010 and 2013 due to concerns about modest benefits and potential side effects, including low blood pressure, dizziness, and fainting, especially when combined with alcohol. The FDA also required special training for prescribers and pharmacists to educate patients about these risks.

The “Even the Score” Campaign and Gender Equity

Following the second rejection, Sprout Pharmaceuticals acquired the rights to flibanserin. Sprout, led by co-founder Cindy Eckert, launched the “Even the Score” public relations campaign. This initiative argued that the lack of approved treatments for female sexual dysfunction, compared to the abundance for men, represented a gender bias in drug approvals. The campaign included parody ads referencing Viagra, aiming to highlight this perceived inequity. This campaign is credited with influencing the FDA’s eventual 2015 approval of Addyi, though it came with a “black box” warning – the most stringent safety warning – regarding the risks associated with alcohol consumption.

Sales Challenges and Expanded Approval

Despite the approval, Addyi’s initial sales fell short of expectations, partly due to a significant price increase and marketing missteps. Valeant Pharmaceuticals acquired Sprout for approximately $1 billion, but the drug was eventually returned to its original shareholders. However, in December 2025, the FDA expanded approval to include postmenopausal women under 65. This expansion occurred despite a warning letter from the FDA to Eckert regarding a social media post that potentially misrepresented the drug’s safety and effectiveness.

Future Trends in Female Sexual Wellness

Addyi’s story highlights a growing awareness of female sexual health needs and the challenges in developing and marketing treatments. Several trends suggest a shift in this landscape:

Beyond Pharmacology: Holistic Approaches

While pharmaceutical options like Addyi and bremelanotide (Vyleesi, an injectable medication also approved for HSDD) are available, there’s increasing interest in holistic approaches. These include sex therapy, mindfulness techniques, pelvic floor exercises, and addressing underlying psychological factors contributing to low libido. The focus is shifting towards a more comprehensive understanding of sexual well-being.

Personalized Medicine and Biomarkers

Future treatments may be tailored to individual needs based on biomarkers and genetic factors. Research is underway to identify biological markers associated with HSDD, potentially leading to more targeted and effective therapies. This personalized approach could minimize side effects and maximize benefits.

Technological Innovations

Technology is playing an increasing role in sexual wellness. Wearable sensors and apps are being developed to track sexual activity, identify patterns, and provide personalized recommendations. Telemedicine platforms are also expanding access to sexual health services, particularly for women in remote areas or those who prefer discreet consultations.

Increased Open Dialogue and Reduced Stigma

The conversation around female sexual health is becoming more open, thanks in part to documentaries like “The Pink Pill” and increased media coverage. This reduced stigma encourages women to seek assist and explore available options without shame or embarrassment.

FAQ

What is HSDD? Hypoactive sexual desire disorder is characterized by persistently low or absent sexual desire for at least six months.

How does Addyi work? Addyi is thought to work by balancing neurotransmitters in the brain that regulate sexual desire.

Is Addyi right for everyone? Addyi is only approved for premenopausal and postmenopausal women (<65) with HSDD and is not without potential side effects.

Are there alternatives to Addyi? Yes, alternatives include bremelanotide (Vyleesi), sex therapy, and lifestyle changes.

Pro Tip: If you’re experiencing persistent low libido, consult with a healthcare professional to discuss potential causes and treatment options.

Want to learn more about women’s health? Explore our articles on hormone therapy and menopause management.

Did you know? Approximately 10% of women are affected by HSDD, yet many do not seek treatment due to stigma or lack of awareness.

Share your thoughts! Have you or someone you know experienced challenges with low libido? Leave a comment below.

0 comments
0 FacebookTwitterPinterestEmail
Health

Colorectal cancer rates surge among adults under 65 across US

by Chief Editor
written by Chief Editor

Colorectal Cancer’s Alarming Rise in Younger Adults: A Deep Dive

Colorectal cancer (CRC), once largely considered a disease of older adults, is now increasingly affecting younger generations. A modern report, “Colorectal Cancer Statistics, 2026,” from the American Cancer Society, reveals a significant shift in incidence, with those 65 and under now accounting for 45% of all new cases – a dramatic increase from 27% in 1995.

The Shifting Demographics of Colorectal Cancer

The most concerning trend is the rapid rise in diagnoses among adults aged 20 to 49, increasing at a rate of 3% per year. This surge has led to colorectal cancer becoming the leading cause of cancer death in adults under 50. While rates are declining in seniors, the younger demographic is experiencing a worrying uptick in the disease.

Currently, approximately 158,850 new cases of colorectal cancer are projected to be diagnosed this year, resulting in 55,230 deaths. The report, published in CA: A Cancer Journal for Clinicians, highlights a particularly troubling statistic: 75% of colorectal cancers in adults 50 and under are diagnosed at an advanced stage. Half of these diagnoses occur between the ages of 45 and 49.

Rectal Cancer on the Rise

Beyond overall colorectal cancer rates, the report also indicates a rise in rectal cancer specifically. Rectal cancer now accounts for about one-third (32%) of all CRC cases, up from 27% in the mid-2000s. This increase adds another layer of complexity to the evolving landscape of this disease.

Screening Rates and the 45-49 Age Group

Despite being eligible for routine screenings, only 37% of individuals in the 45-49 age group actually undergo them. This low screening rate contributes to the higher proportion of advanced-stage diagnoses in younger adults. Early detection is crucial, as the five-year survival rate for localized (early-stage) colorectal cancer is 95%.

What’s Driving This Increase?

Rebecca Siegel, senior scientific director at the American Cancer Society and lead author of the report, emphasizes the need for further research. “After decades of progress, the risk of dying from colorectal cancer is climbing in younger generations of men and women, confirming a real uptick in disease because of something we’re doing or some other exposure,” she stated. Researchers are investigating potential contributing factors, but a definitive cause remains elusive.

More than half of CRC cases are linked to modifiable risk factors, including poor nutrition, high alcohol consumption, smoking, lack of exercise, and obesity. Addressing these lifestyle factors could potentially mitigate the rising incidence of the disease.

The Importance of Early Detection and Research

Dr. William Dahut, chief scientific officer at the American Cancer Society, underscores the importance of continued research and increased screening. “These findings further underscore that colorectal cancer is worsening among younger generations and highlight the immediate need for eligible adults to start screening at the recommended age of 45,” he said. “The report also shines a light on the crucial importance of continued funding for research to help discover new therapies to treat the disease and advance patient care.”

Frequently Asked Questions

What is colorectal cancer? Colorectal cancer is a cancer that starts in the colon or rectum.

Who is at risk? While anyone can develop colorectal cancer, risk factors include age, family history, lifestyle choices, and certain medical conditions.

When should I start getting screened? Current guidelines recommend that individuals begin regular screenings at age 45.

What are the symptoms of colorectal cancer? Symptoms can include changes in bowel habits, rectal bleeding, abdominal discomfort, and unexplained weight loss.

Is colorectal cancer preventable? Adopting a healthy lifestyle, including a balanced diet, regular exercise, and avoiding smoking, can help reduce your risk.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts